Comparative Pharmacology
Head-to-head clinical analysis: CROMOPTIC versus GASTROCROM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CROMOPTIC versus GASTROCROM.
CROMOPTIC vs GASTROCROM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mast cell stabilizer that inhibits the release of histamine and other inflammatory mediators from mast cells. Also inhibits eosinophil chemotaxis and activation.
Mast cell stabilizer; inhibits degranulation of mast cells and release of histamine and other inflammatory mediators.
1-2 drops in each eye 4 times daily for conjunctivitis; 1 drop in each eye 2-4 times daily for allergic conjunctivitis prophylaxis.
200 mg orally four times daily, 30 minutes before meals and at bedtime.
None Documented
None Documented
1.3 hours (terminal elimination half-life); clinically, due to rapid elimination, dosing is required 4 times daily for sustained effect.
Terminal elimination half-life is approximately 1–1.5 hours following intravenous administration. The apparent half-life after oral inhalation is longer due to slow absorption from the lungs, but systemic half-life remains short, requiring frequent dosing for sustained effect.
Primarily renal excretion of unchanged drug (approximately 70% within 24 hours); the remainder is excreted in feces via biliary elimination (approximately 30%).
Primarily excreted unchanged in bile and feces via enterohepatic circulation; renal excretion accounts for approximately 1-2% of an oral dose. After intravenous administration, about 50% is excreted unchanged in urine within 48 hours.
Category C
Category C
Mast Cell Stabilizer
Mast Cell Stabilizer